🩹 Topical Corticosteroid & Vitamin D Analog Simulator

How Topical Corticosteroids Calm Psoriatic Inflammation

Placeholder: steroids suppress immune signaling in psoriatic plaques.

• GR: Receptor (Placeholder short note)
• Days: Onset (Placeholder short note)
• 7: Potency classes (Placeholder short note)
• ↓ IL-17/23: Cytokines (Placeholder short note)

Glucocorticoid receptor signaling

Placeholder: steroid diffuses into keratinocytes and binds cytoplasmic receptor.

Vasoconstriction and cytokine suppression

Placeholder: reduces vasodilation, cytokine transcription, and cell trafficking.

Placeholder: potent steroids act fast but carry higher atrophy risk.

Vitamin D Analog Normalization of Keratinocyte Turnover

Placeholder: calcipotriol corrects abnormal keratinocyte proliferation.

• VDR: Receptor (Placeholder short note)
• Weeks: Onset (Placeholder short note)
• Low: Atrophy risk (Placeholder short note)
• ↓ Proliferation: Effect (Placeholder short note)

Vitamin D receptor activation

Placeholder: binds VDR, regulates keratinocyte differentiation genes.

Slower but atrophy-sparing action

Placeholder: takes longer to work but does not thin the skin.

Placeholder: good long-term option without steroid side effects.

Steroid Plus Calcipotriol — Complementary Mechanisms

Placeholder: combining agents targets inflammation and proliferation together.

• +: Efficacy gain (Placeholder short note)
• Yes: Steroid sparing (Placeholder short note)
• Fixed-dose: Formulation (Placeholder short note)
• Improved: Tolerability (Placeholder short note)

Complementary pathways

Placeholder: anti-inflammatory and antiproliferative actions combine.

Reduced cumulative steroid exposure

Placeholder: combination allows lower steroid potency or frequency.

Placeholder: combination often preferred as first-line regimen.

Epidermal and Dermal Thinning from Prolonged Steroid Use

Placeholder: chronic steroid exposure thins skin layers over time.

• ~3-4 wk: Risk onset (Placeholder short note)
• ↓ Synthesis: Collagen (Placeholder short note)
• Partial: Reversibility (Placeholder short note)
• Face/folds: High-risk sites (Placeholder short note)

Fibroblast suppression

Placeholder: steroids reduce collagen and fibroblast activity.

Clinical signs of atrophy

Placeholder: telangiectasia, striae, and fragile skin appear.

Placeholder: risk rises sharply with prolonged continuous use.

Cyclical Dosing to Balance Efficacy and Safety

Placeholder: time-capped and weekend-only regimens limit atrophy.

• 2-4 wk: Typical cap (Placeholder short note)
• Vit D: Maintenance (Placeholder short note)
• Weekend: Pulse dosing (Placeholder short note)
• Periodic: Monitoring (Placeholder short note)

Step-down and rotation strategies

Placeholder: taper steroid potency and rotate with vitamin D analog.

Long-term maintenance plan

Placeholder: calcipotriol maintenance minimizes relapse and atrophy.

Placeholder: duration limits protect skin integrity long-term.